Oncogenesis - Activation of the AKT/cyclin D1/Cdk4 survival signaling pathway in radioresistant cancer stem cells Skip to main content Thank you for visiting nature.com.

Cyclin D–CDK4/6 pathway activity is regulated by a number of mitogenic signals, including epidermal growth factors, signaling through the HER2 and estrogen receptors, and the phosphoinositide 3-kinase ...

Current data support the use of CDK4/6 inhibitors in sarcomas primarily driven by CDK4/6 signaling. In sarcomas where Rb pathway dysregulation is a secondary driver, combinations of CDK4/6 inhibition ...

Implications for the AKT–mTOR Signaling Pathway and Cancer Treatment. The AKT–mTOR pathway plays a pivotal role in cell growth, ... Proteomic Profiling Predicts Response to CDK4/6 inhibitors: ...

"Now, we want to evaluate what signaling pathway earlier in the cell division process leads to CDK7 activation, so that it can in turn activate CDK4 and CDK6. This pathway may be an important ...

Clinical Challenges: Beyond CDK4/6 Inhibition in Advanced HR-Positive Breast Cancer ... In contrast, targeting downstream signaling through the PI3K/AKT/mTOR pathway appears to be effective.

The CDK4/6 inhibitors-resistant breast cancer cells expressed more Cyclin D1 and CDK4 proteins than the parental cells (Upper left). PI3K pathway was hyper-activated in the resistant cells (Upper ...

More importantly, targeting PI3K/mTOR pathway reduced the protein levels of Cyclin D1/CDK4 and restored the sensitivity to palbociclib in its resistant cells, suggesting the feasibility and ...

CARM1 regulates genes involved in key signaling pathways such as HIF-1, Wnt, and VEGF, contributing to TNBC progression. CARM1 physically associates with HIF1A, and this interaction is crucial for ...